Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial - Critical Care

Ireland News News

Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial - Critical Care
Ireland Latest News,Ireland Headlines
  • 📰 BioMedCentral
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 71%

An analysis of the STARRT-AKI trial published in Crit_Care finds that accelerated renal replacement therapy initiation in critically ill patients with acute kidney injury confers a modest reduction of cumulative fluid balance.

]. STARRT-AKI was registered at ClinicalTrials.gov . Ethics approval was granted by research ethics boards at all participating sites, and consent to participate was provided by patients or substitute decision makers; deferred or waived consent was permitted in certain jurisdictions as per local policy.

This planned secondary analysis aimed to evaluate the effect of an accelerated strategy of RRT initiation on fluid accumulation. First, among the 2927 patients who were eligible for the modified intention to treat analysis, we evaluated the difference in cumulative fluid balance, by randomized group, from the day of randomization through their entire ICU stay or up to day 14.

We evaluated effect estimates for each of the outcomes of interest within each quartile: risk ratios for categorical outcomes were estimated using binomial general linear models with log-links, andvalue for trends was estimated as the interaction between quartile and outcome in the models. Mean differences for continuous outcomes were evaluated with

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

BioMedCentral /  🏆 22. in UK

Ireland Latest News, Ireland Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

A plea for personalization of the hemodynamic management of septic shock - Critical CareA plea for personalization of the hemodynamic management of septic shock - Critical CareAlthough guidelines provide excellent expert guidance for managing patients with septic shock, they leave room for personalization according to patients’ condition. Hemodynamic monitoring depends on the evolution phase: salvage, optimization, stabilization, and de-escalation. Initially during the salvage phase, monitoring to identify shock etiology and severity should include arterial pressure and lactate measurements together with clinical examination, particularly skin mottling and capillary refill time. Low diastolic blood pressure may trigger vasopressor initiation. At this stage, echocardiography may be useful to identify significant cardiac dysfunction. During the optimization phase, echocardiographic monitoring should be pursued and completed by the assessment of tissue perfusion through central or mixed-venous oxygen saturation, lactate, and carbon dioxide veno-arterial gradient. Transpulmonary thermodilution and the pulmonary artery catheter should be considered in the most severe patients. Fluid therapy also depends on shock phases. While administered liberally during the resuscitation phase, fluid responsiveness should be assessed during the optimization phase. During stabilization, fluid infusion should be minimized. In the de-escalation phase, safe fluid withdrawal could be achieved by ensuring tissue perfusion is preserved. Norepinephrine is recommended as first-line vasopressor therapy, while vasopressin may be preferred in some patients. Essential questions remain regarding optimal vasopressor selection, combination therapy, and the most effective and safest escalation. Serum renin and the angiotensin I/II ratio may identify patients who benefit most from angiotensin II. The optimal therapeutic strategy for shock requiring high-dose vasopressors is scant. In all cases, vasopressor therapy should be individualized, based on clinical evaluation and blood flow measurements to avoid excessive vasoconstriction. Inotropes should be considered in patients w
Read more »

Trans woman suffered ‘morning sickness’ after starting hormone treatmentTrans woman suffered ‘morning sickness’ after starting hormone treatmentA trans woman says she suffered ‘morning sickness’ after starting oestrogen but said ‘it was worth it’ for her incredible transformation.
Read more »

A plea for personalization of the hemodynamic management of septic shock - Critical CareA plea for personalization of the hemodynamic management of septic shock - Critical CareAlthough guidelines provide excellent expert guidance for managing patients with septic shock, they leave room for personalization according to patients’ condition. Hemodynamic monitoring depends on the evolution phase: salvage, optimization, stabilization, and de-escalation. Initially during the salvage phase, monitoring to identify shock etiology and severity should include arterial pressure and lactate measurements together with clinical examination, particularly skin mottling and capillary refill time. Low diastolic blood pressure may trigger vasopressor initiation. At this stage, echocardiography may be useful to identify significant cardiac dysfunction. During the optimization phase, echocardiographic monitoring should be pursued and completed by the assessment of tissue perfusion through central or mixed-venous oxygen saturation, lactate, and carbon dioxide veno-arterial gradient. Transpulmonary thermodilution and the pulmonary artery catheter should be considered in the most severe patients. Fluid therapy also depends on shock phases. While administered liberally during the resuscitation phase, fluid responsiveness should be assessed during the optimization phase. During stabilization, fluid infusion should be minimized. In the de-escalation phase, safe fluid withdrawal could be achieved by ensuring tissue perfusion is preserved. Norepinephrine is recommended as first-line vasopressor therapy, while vasopressin may be preferred in some patients. Essential questions remain regarding optimal vasopressor selection, combination therapy, and the most effective and safest escalation. Serum renin and the angiotensin I/II ratio may identify patients who benefit most from angiotensin II. The optimal therapeutic strategy for shock requiring high-dose vasopressors is scant. In all cases, vasopressor therapy should be individualized, based on clinical evaluation and blood flow measurements to avoid excessive vasoconstriction. Inotropes should be considered in patients w
Read more »



Render Time: 2025-04-02 01:29:18